Cyclerion Therapeutics Inc
CYCN
NASDAQ
Biotechnology
$3.79
USD
-0.12 (-3.07%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $18.54M
Volume 24.2K
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
CEO
Dr. Regina Graul
HQ
Cambridge, MASSACHUSETTS, US
Founded
2019
Employees
1
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on CYCN.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
-12.6%
—
Gross Margin (TTM)
100.0%
0.0 pp
Operating Margin (TTM)
-359.2%
-186.4 pp
Net Margin (TTM)
-353.0%
-263.5 pp
ROE (TTM)
-131.8%
-109.1 pp
Free Cash Flow (TTM)
$-4.52M
—
Financial Snapshot
Revenue
$1.90M
-12.6%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-6.71M
-244.7%
YoY
Operating Cash Flow
$-4.45M
-57.4%
YoY
Key Statistics
Open
$3.85
Previous Close
$3.91
Day Range
$3.73 - $3.97
52 Week Range
$1.03 - $8.48
Volume
24.2K
Average Volume (10 Days)
20.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$18.54M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
9.76
Price / Book
3.64
Financial Highlights
Profit Margin
-353.0%
Return on Assets
-96.8%
Return on Equity
-131.8%
Revenue (TTM)
$1.90M
Net Income (TTM)
$-6.71M
Diluted EPS (TTM)
-$1.68
Total Cash (MRQ)
$1.39M
Levered FCF (TTM)
$-4.52M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 10